PCVX · Vaxcyte, Inc. · Executive Compensation
$60.16
+1.64 (+2.80%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$9.26B
Shares
158.30M
Volume · Nov 19
172.87K
Avg daily vol (3M)
2.16M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Grant Pickering | Chief Executive Officer | $14,458,937 |
| Andrew Guggenhime | President and Chief Financial Officer | $6,072,939 |
| Jim Wassil | Executive Vice President and Chief Operating Officer | $5,809,971 |
| Mikhail Eydelman | Senior Vice President, General Counsel and Corporate Secretary | $4,005,935 |
| Harp Dhaliwal | Chief Technical Operations Officer | $3,764,679 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Grant Pickering | Chief Executive Officer | $39,639,512 |
| Andrew Guggenhime | President and Chief Financial Officer | $17,878,117 |
| Jim Wassil | Executive Vice President and Chief Operating Officer | $17,867,617 |
| Mikhail Eydelman | Senior Vice President, General Counsel and Corporate Secretary | $5,663,443 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Grant Pickering | Chief Executive Officer | $12,135,684 |
| Andrew Guggenhime | President and Chief Financial Officer | $5,415,277 |
| Jim Wassil | Executive Vice President and Chief Operating Officer | $5,401,215 |
| Mikhail Eydelman | Senior Vice President, General Counsel and Corporate Secretary | $3,492,348 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Grant Pickering | Chief Executive Officer | $13,661,941 |
| Jim Wassil | Executive Vice President and Chief Operating Officer | $6,991,203 |
| Andrew Guggenhime | President and Chief Financial Officer | $6,902,093 |
| Mikhail Eydelman | Senior Vice President, General Counsel and Corporate Secretary | $5,013,144 |
| Paul Sauer | Senior Vice President, Process Development and Manufacturing | $2,354,242 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Grant Pickering | Chief Executive Officer | $5,291,474 |
| Andrew Guggenhime | President and Chief Financial Officer | $2,753,001 |
| Jim Wassil | Executive Vice President and Chief Operating Officer | $1,970,336 |
| Paul Sauer | Senior Vice President, Process Development and Manufacturing | $1,087,630 |
| Mikhail Eydelman | Senior Vice President, General Counsel and Corporate Secretary | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Andrew Guggenhime | President and Chief Financial Officer | $5,650,072 |
| Grant Pickering | Chief Executive Officer | $3,374,620 |
| Jim Wassil | Executive Vice President and Chief Operating Officer | $1,357,549 |
| Paul Sauer | Senior Vice President, Process Development and Manufacturing | $904,518 |
| Mikhail Eydelman | Senior Vice President, General Counsel and Corporate Secretary | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David McAvoy | Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary | Appointed | 2026-09-03 |
| John Markels | Class II director | Appointed | 2026-07-15 |
|
Heath Lukatch
“Dr. Lukatch’s retirement was not the result of any disagreement or dispute with the Company.”
|
Board of Directors | Retired | 2026-07-15 |
| Moncef Slaoui | Class II director | Appointed | 2026-06-23 |
|
Jacks Lee
“Mr. Lee’s retirement was not the result of any disagreement or dispute with the Company.”
|
Board | Retired | 2026-06-23 |
| Dr. Olivier Brandicourt | Class III director | Appointed | 2025-05-01 |
| John P. Furey | Class II director | Appointed | 2024-07-02 |
| Jacks Lee | Class II director | Appointed | 2023-11-28 |
| Elvia Cowan | principal accounting officer | Appointed | 2022-12-12 |
| Carlos V. Paya, M.D., Ph.D. | Chair of the Board | Appointed | 2021-10-28 |
| Michael Kamarck, Ph.D. | Class III director | Appointed | 2021-10-28 |
| Carlos V. Paya, M.D., Ph.D. | Class I director | Appointed | 2021-10-28 |
| Annie Drapeau | Class I directors | Appointed | 2021-09-20 |
| Teri Loxam | Class I directors | Appointed | 2021-09-20 |
| Rob Hopfner | a director of the Company and member of the Nominating and Corporate Governance Committee | Resigned | 2021-09-20 |
| Patrick Heron | a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee | Resigned | 2021-09-20 |
Leadership
- Grant Pickering CEO, Board Member
- Carlos V. Paya, M.D., Ph.D. Chairman, Board Member
- Andrew Guggenhime CFO
- Jim Wassil COO
- Mikhail Eydelman General Counsel
- Elvia Cowan Chief Accounting Officer
- Dr. Olivier Brandicourt Board Member
- Halley Gilbert Board Member
- Jacks Lee Board Member
- John Markels Board Member
- John P. Furey Board Member
- Michael Kamarck, Ph.D. Board Member
- Moncef Slaoui Board Member
- Olivier Brandicourt Board Member
Key facts
CIK
1649094
CUSIP
92243G108
13F (30d)
372 filings
338 filers
Visit website
Investor relations